Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HMGCR | P04035 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19792815 | 0.83 | GABBR2 (0.41) | TSHRHMGCRTP53TDP1POLB | |
| SCHEMBL12876259 | 0.82 | TSHR (0.42) | TSHRHMGCRTP53TDP1POLB | |
| SCHEMBL19792824 | 0.82 | CYP1A2 (0.41) | FDPSTSHRHMGCRPOLB | |
| SCHEMBL13334729 | 0.76 | FDPS (0.52) | FDPSTSHRHMGCRTP53TDP1 | |
| SCHEMBL2821620 | 0.76 | POLB (0.44) | FDPSTSHRTP53TDP1POLB | |
| SCHEMBL12876198 | 0.75 | FDPS (0.50) | FDPSTSHRTP53TDP1PPARD | |
| SCHEMBL9652021 | 0.74 | TSHR (0.48) | TSHRHMGCRTP53TDP1POLB | |
| SCHEMBL19939425 | 0.74 | TSHR (0.37) | TSHRHMGCRTP53TDP1POLB | |
| SCHEMBL28362519 | 0.72 | FDPS (0.64) | FDPSTSHRTP53TDP1PPARD | |
| SCHEMBL14010336 | 0.71 | TSHR (0.40) | FDPSTSHRTP53TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034714-A1 | METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND | EKIMOTO HISAO | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034714-A1 | METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND | NR3C2, NR3C1, MC5R | FDPS 4834/4885TSHR 1365/4885HMGCR 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.